Aureka opened its drug discovery platform as AI biotech continues to move toward more lab-linked systems. The company released Open Drug Discovery Engine (OpenDDE), an open-source, all-atom biomolecular foundation model intended to help model protein and nucleic-acid interactions at atomic resolution. Aureka’s release is positioned as a preview rather than a complete end-to-end drug-discovery machine. The company says OpenDDE’s initial capabilities center on structure modeling and co-folding, while downstream functions—molecular design, affinity prediction, active learning, and experimental feedback—require further validation. By publishing the model under an Apache-2.0 license and providing implementation support such as Docker, Aureka is attempting to gain technical credibility in a field where AI models are frequently kept proprietary behind closed workflows. The company’s framing also draws a boundary: the open technical artifact is separated from Aureka’s internal wet-lab and experimental feedback loops, which remain part of its business model.